CL2004000564A1 - Formulacion farmaceutica para administracion oral que comprende uno o mas agentes farmaceuticamente activos y cacao en polvo. - Google Patents
Formulacion farmaceutica para administracion oral que comprende uno o mas agentes farmaceuticamente activos y cacao en polvo.Info
- Publication number
- CL2004000564A1 CL2004000564A1 CL200400564A CL2004000564A CL2004000564A1 CL 2004000564 A1 CL2004000564 A1 CL 2004000564A1 CL 200400564 A CL200400564 A CL 200400564A CL 2004000564 A CL2004000564 A CL 2004000564A CL 2004000564 A1 CL2004000564 A1 CL 2004000564A1
- Authority
- CL
- Chile
- Prior art keywords
- oral administration
- active agents
- pharmaceutical formulation
- pharmaceutically active
- cocoa powder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Botany (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Alternative & Traditional Medicine (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0300831A SE0300831D0 (sv) | 2003-03-26 | 2003-03-26 | New formulations and use therof |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2004000564A1 true CL2004000564A1 (es) | 2005-02-04 |
Family
ID=20290786
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL200400564A CL2004000564A1 (es) | 2003-03-26 | 2004-03-18 | Formulacion farmaceutica para administracion oral que comprende uno o mas agentes farmaceuticamente activos y cacao en polvo. |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1605921A1 (ja) |
JP (2) | JP2006521348A (ja) |
CN (1) | CN1764440A (ja) |
AR (1) | AR043772A1 (ja) |
AU (1) | AU2004224557B2 (ja) |
BR (1) | BRPI0408655A (ja) |
CA (1) | CA2519155A1 (ja) |
CL (1) | CL2004000564A1 (ja) |
MX (1) | MXPA05010196A (ja) |
SE (1) | SE0300831D0 (ja) |
TW (1) | TW200503782A (ja) |
WO (1) | WO2004084865A1 (ja) |
ZA (1) | ZA200507719B (ja) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE526950T1 (de) | 1999-10-29 | 2011-10-15 | Euro Celtique Sa | Hydrocodon-formulierungen mit gesteuerter freisetzung |
US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
WO2002036099A1 (en) | 2000-10-30 | 2002-05-10 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
CN101237850A (zh) * | 2005-08-02 | 2008-08-06 | 德罗萨帕尔姆股份公司 | 含有吲哚美辛和/或阿西美辛的药物组合物 |
US20080069891A1 (en) | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
US8445018B2 (en) | 2006-09-15 | 2013-05-21 | Cima Labs Inc. | Abuse resistant drug formulation |
KR101660666B1 (ko) | 2007-06-13 | 2016-09-27 | 오츠카 세이야쿠 가부시키가이샤 | 에쿠올을 포함하는 식품 |
CN101444273B (zh) * | 2007-11-22 | 2013-04-24 | 何煜 | 一种保健品口腔速释制剂及其制造方法 |
WO2009070978A1 (fr) * | 2007-11-22 | 2009-06-11 | Yu He | Libération rapide dans la cavité buccale des produits de santé et procédé de préparation associé |
CN101439053A (zh) * | 2007-11-22 | 2009-05-27 | 何煜 | 一种中药口腔速释制剂及其制造方法 |
BRPI1012170A2 (pt) * | 2009-05-20 | 2016-03-29 | Lingual Consegna Pty Ltd | formulação e/ou sublingual e método para reduzir a quantidade de composto ativo usado para alcançar um efeito em um paciente em comparação com um composto típico que é ingerido. |
US8263581B2 (en) | 2009-07-03 | 2012-09-11 | Jdp Therapeutics, Inc. | Non-sedating antihistamine injection formulations and methods of use thereof |
US8513259B2 (en) | 2009-07-03 | 2013-08-20 | Jdp Therapeutics, Inc. | Non-sedating antihistamine injection formulations and methods of use thereof |
MX2012012991A (es) | 2010-05-11 | 2012-11-30 | Cima Labs Inc | Formas de dosificacion oral de liberacion prolongada resistentes al alcohol y que contienen metoprolol. |
US20160000714A1 (en) | 2013-03-06 | 2016-01-07 | Capsugel Belgium Nv | Curcumin solid lipid particles and methods for their preparation and use |
CN103583781B (zh) * | 2013-11-01 | 2015-11-25 | 阳波 | 咖啡味甲硝唑口香糖 |
US20170112762A1 (en) * | 2014-06-10 | 2017-04-27 | Capsugel Belgium Nv | Orally disintegrating tablet containing solid lipid particles and methods for their preparation and use |
US11324699B2 (en) | 2014-12-04 | 2022-05-10 | Capsugel Belgium Nv | Lipid multiparticulate formulations |
JP6334482B2 (ja) * | 2015-08-28 | 2018-05-30 | 中野Bc株式会社 | 固形剤とその製造方法 |
CA3176596A1 (en) * | 2015-12-09 | 2017-06-15 | Poviva Corp. | Methods for formulating orally ingestible compositions comprising lipophilic active agents |
US20180116240A1 (en) * | 2015-12-09 | 2018-05-03 | Poviva Tea, Llc | Stable ready-to-drink beverage compositions comprising lipophilic active agents |
US11331268B2 (en) | 2016-11-18 | 2022-05-17 | The University Of Western Australia | Taste masking product |
CA3092458C (en) * | 2018-03-01 | 2024-01-30 | Lts Lohmann Therapie-Systeme Ag | Oral dosage form containing theobromine-free cocoa |
CN109053718B (zh) * | 2018-08-09 | 2022-06-03 | 天津理工大学 | 一种罗格列酮糖精盐及其制备方法 |
CN111729087A (zh) * | 2020-07-24 | 2020-10-02 | 成都大学 | 一种选择性β2受体激动剂的脂质修饰物及其制备方法与用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB785574A (en) * | 1955-03-29 | 1957-10-30 | Pfizer & Co C | Pharmaceutical compositions containing tetracycline antibiotics |
GB918955A (en) * | 1960-05-19 | 1963-02-20 | Thomae Gmbh Dr K | Pharmaceutical laxative compositions comprising 4,4-dihydroxy-2-amino triphenylmethane |
FR2717387B1 (fr) * | 1994-03-17 | 1996-10-18 | Hi Pharmtech | Procédé de fabrication de comprimés à croquer à base de troxérutine, de carbonate de calcium, de phosphate de calcium, d'aspartate d'arginine, de glutamate d'arginine d'amoxicilline. |
SE9803986D0 (sv) * | 1998-11-23 | 1998-11-23 | Pharmacia & Upjohn Ab | New compositions |
JP2001106641A (ja) * | 1999-10-06 | 2001-04-17 | Tendou Seiyaku Kk | 口内薬 |
JP2001114668A (ja) * | 1999-10-13 | 2001-04-24 | Meiji Seika Kaisha Ltd | チョコレート剤 |
JP2002193839A (ja) * | 2000-12-27 | 2002-07-10 | Meiji Seika Kaisha Ltd | ココア製剤 |
US20020172732A1 (en) * | 2001-03-21 | 2002-11-21 | Wies Ter Laak | Composition comprising cocoa |
SE0103211D0 (sv) * | 2001-09-27 | 2001-09-27 | Pharmacia Ab | New formulations and use thereof |
-
2003
- 2003-03-26 SE SE0300831A patent/SE0300831D0/xx unknown
-
2004
- 2004-03-16 WO PCT/IB2004/000860 patent/WO2004084865A1/en active Application Filing
- 2004-03-16 EP EP04720946A patent/EP1605921A1/en not_active Withdrawn
- 2004-03-16 BR BRPI0408655-4A patent/BRPI0408655A/pt not_active IP Right Cessation
- 2004-03-16 CA CA002519155A patent/CA2519155A1/en not_active Abandoned
- 2004-03-16 AU AU2004224557A patent/AU2004224557B2/en not_active Ceased
- 2004-03-16 JP JP2006506377A patent/JP2006521348A/ja not_active Withdrawn
- 2004-03-16 MX MXPA05010196A patent/MXPA05010196A/es unknown
- 2004-03-16 CN CNA2004800077898A patent/CN1764440A/zh active Pending
- 2004-03-18 CL CL200400564A patent/CL2004000564A1/es unknown
- 2004-03-23 TW TW093107802A patent/TW200503782A/zh unknown
- 2004-03-24 AR ARP040100981A patent/AR043772A1/es not_active Application Discontinuation
-
2005
- 2005-09-23 ZA ZA200507719A patent/ZA200507719B/en unknown
-
2010
- 2010-11-15 JP JP2010255113A patent/JP2011079841A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
MXPA05010196A (es) | 2005-11-08 |
JP2011079841A (ja) | 2011-04-21 |
SE0300831D0 (sv) | 2003-03-26 |
BRPI0408655A (pt) | 2006-03-28 |
AU2004224557B2 (en) | 2009-06-18 |
CA2519155A1 (en) | 2004-10-07 |
WO2004084865A1 (en) | 2004-10-07 |
ZA200507719B (en) | 2007-09-26 |
AR043772A1 (es) | 2005-08-10 |
JP2006521348A (ja) | 2006-09-21 |
CN1764440A (zh) | 2006-04-26 |
EP1605921A1 (en) | 2005-12-21 |
TW200503782A (en) | 2005-02-01 |
AU2004224557A1 (en) | 2004-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2004000564A1 (es) | Formulacion farmaceutica para administracion oral que comprende uno o mas agentes farmaceuticamente activos y cacao en polvo. | |
NO20043702L (no) | 8-azaprostaglandinderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel | |
HUP0500846A2 (en) | Pharmaceutical formulation with an insoluble active agent for pulmonary administration | |
CY2011013I1 (el) | Στερεες φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν εναν αγωνιστη υποδοχεα s1p και μια αλκοολη σακχαρων | |
IL191804A0 (en) | Solid dispersion containing an active ingredient and tablets for oral administration containing the same | |
DK1498411T3 (da) | Diketohydrazinderivatforbindelser og medikamenter indeholdende forbindelserne som den aktive bestanddel | |
MY149623A (en) | Sprayable gel-type skin/mucosa-adhesive preparation and administration system using the preparation | |
ATE354362T1 (de) | Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff | |
ZA200605631B (en) | Directly compressible pharmaceutical composition for the oral administration of CCI-779 | |
ITMI20011337A0 (it) | Composizioni farmaceutiche orali a rilascio modificato del principio attivo | |
IL216931A0 (en) | Pharmaceutical formulation that comprisies azelastine and fluticasone and aproduct comprising these as antihistamine and anti - inflammatory agent | |
NO20043904L (no) | Oral doseringsform inneholdende en PDE4-hemmer som aktivt ingrediens og polyvinylpyrrolidon som eksipiens | |
NO20054244D0 (no) | Nitrogeninneholdende heterocykliske derivater og legemidler inneholdende de samme som den aktive bestanddel | |
EP1660043A4 (en) | FORMULATION WITH IMMEDIATE RELEASE OF ACID ELASTIC PHARMACEUTICAL COMPOSITIONS | |
ZA200705750B (en) | Compositions and methods for stabilizing active pharmaceutical ingredients | |
HUP0302319A3 (en) | Pharmaceutical composition for oral administration of active ingredient | |
DK1557415T3 (da) | Heterocykliske forbindelser og antitumorlægemidler indeholdende samme som den aktive ingrediens | |
IL173847A0 (en) | Pharmaceutical composition in a form of anhydrous self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs | |
DE60020501D1 (de) | Trimetazidinhaltige Matrixtablette zur verlängerten Wirkstofffreisetzung nach oraler Gabe | |
PL1655026T3 (pl) | Zawierające diacereinę i meloksikam stałe preparaty farmaceutyczne | |
PT1210119E (pt) | Composicoes farmaceuticas para administracao oral e topica | |
ITMI20011338A0 (it) | Composizioni farmaceutiche orali a rilascio immediato del principio attivo | |
HK1098962A1 (en) | Antimycobacterial pharmaceutical composition comprising an antitubercular drug | |
NO20026055L (no) | Farmasöytiske komponenter innbefattende humant paratyreoideahormon og farmasöytiske sammenstninger for nasal administrering inneholdendekomponentene | |
IL172096A0 (en) | Pharmaceutical formulations comprising amoxicillin and clavulanate |